Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
155 results about "Monoamine oxidase inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as powerful anti-depressants, as well as effective therapeutic agents for panic disorder and social phobia. They are particularly effective in treatment-resistant depression and atypical depression. They are also used in the treatment of Parkinson's disease and several other disorders.
Lithium combinations, and uses related thereto
InactiveUS20050233010A1Prevent precipitating manic episodeLessening and preventing riskBiocideNervous disorderPsychoactive drugAdrenergic antagonist
The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
Owner:NOVEN THERAPEUTICS
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
ActiveUS20090005456A1Improve usabilityOrganic active ingredientsBiocideSynaptic cleftPharmaceutical formulation
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat / prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
Owner:SUNOVION PHARMA INC
Pyrazolo pyridine derivatives as nadph oxidase inhibitors
The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and / or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
Owner:CALLIDITAS THERAPEUTICS SUISSE SA
Pyrazolo pyridine derivatives as nadph oxidase inhibitors
The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and / or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
Owner:CALLIDITAS THERAPEUTICS SUISSE SA
Tetralone-based monoamine reuptake inhibitors
ActiveUS8053603B2Increase synaptic availabilityImprove usabilityBiocideNervous disorderDiseaseSynaptic cleft
The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.
Owner:SUNOVION PHARMA INC
Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
InactiveUS20110311620A1Facilitated releaseBiocidePowder deliveryXanthine oxidase inhibitorModified Release Dosage Form
Owner:TAKEDA PHARMA U S A
Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter
Methods and compositions for treatment of a patient suffering from a form of peripheral neuropathy are disclosed. The method comprises administering to the patient any one of the following combinations of components: I. A, B and C; II. A and B; III. B and C; IV. A and C, wherein A is an antidepressant or a monoamine oxidase inhibitor, B is vitamin B12, and C is a precursor or inducer of a neurotransmitter, e.g. L-phenylalanine.
Owner:THE WWK TRUST
Pyrazolo pyridine derivatives as nadph oxidase inhibitors
Owner:GENKYOTEX SUISSE SA
Method for screening xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry
ActiveCN102095825AQuick checkAccurate detectionComponent separationMass spectrometry imagingGenistein
The invention provides a method for screening a xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry. The method is used for analyzing the in-vitro inhibition rate of the extract or monomer of a natural product on the xanthine oxidase and the catalytic activity of the xanthine oxidase. By using the ultra performance liquid chromatography-mass spectrometry in the xanthine oxidase inhibitor screening, the method is rapid and accurate in sample detection, and the correlation coefficients of the linear equation reaches 0.998. The mass spectrometry has high accuracy and good specificity in detecting the mass electron ratio of a compound, and can be used for screening the xanthine oxidase inhibitor and for the kinetic study of the xanthine oxidase inhibitor without false positive and false negative results which occur in the spectrometry. The results showed that the inhibition rate I of 20 mumol / L allopurinol is 80%; the inhibition rate of 20 mumol / L isorhamnetin is 73%; the inhibition rate of 20 mumol / L genistein is 50%; and the inhibition rate of 0.1 mg / mL aqueous extract of Ginkgo biloba is 27%.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
Owner:LG CHEM LTD
Monoamine reuptake inhibitors
The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Owner:RES TRIANGLE INST
Lithium combinations, and uses related thereto
InactiveUS20080107756A1Prevent precipitating manic episodeLessening and preventing riskBiocideNervous disorderNorepinephrine reuptake inhibitorPsychoactive drug
The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
Owner:NOVEN THERAPEUTICS
Amide compound and application thereof in preparing monoamine oxidase inhibitor
ActiveCN101982170AStable in natureHigh purityOrganic active ingredientsNervous disorderAmine oxidase inhibitorsFluorescence
The invention provides a new amide compound shown as structural formula (I) and application thereof in preparing monoamine oxidase inhibitor. The invention takes phenols compound shown as formula (II) and 2-chloroacetamide shown as formula (III) as reaction substrate, reaction is taken place to obtain amide compound shown as the formula (I), and then fluorescence detection method is used for detecting monoamine oxidase inhibition activity. The method has simple operation process, raw materials are available, and the obtained monoamine oxidase inhibitor has stable properties, and purity is high (more than 99%); compared with the previously researched method of monoamine oxidase inhibitor, the sieved novel amide monoamine oxidase inhibitor has simple structure, and inhibition activity and selectivity on MAO-A and MAO-B are all greatly improved.
Owner:日照新睿招商发展有限公司
Pyrazoline dione derivatives as nadph oxidase inhibitors
The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and / or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
Owner:GENKYOTEX SUISSE SA
Application of arachidonic acid as xanthine oxidase inhibitor and in preparation of medicines for treating hyperuricemia or gout
ActiveCN102133214ASave energyInhibitory activityOrganic active ingredientsSkeletal disorderIsrapafantMonoamine oxidase inhibitor
The invention relates to application of arachidonic acid as a xanthine oxidase inhibitor and in the preparation of medicines for treating hyperuricemia or gout. Xanthine oxidase is a key enzyme for the generation and the development of the hyperuricemia or the gout, most substrates of the xanthine oxidase are cyclic small molecules, and the arachidonic acid is long chain polyunsaturated fatty acid; a three dimensional structure of the xanthine oxidase is downloaded from a protein data bank (PDB) of a website; a three dimensional structure of the arachidonic acid is downloaded from a pubchem; molecular docking between the arachidonic acid and the xanthine oxidase is performed by iGEMDOCK software and docking energy is computed; and in-vitro enzyme activity tests prove that the arachidonic acid has an inhibition effect on the xanthine oxidase. By the application, another important physiological function of the arachidonic acid is discovered, and a wider way is provided for screening the xanthine oxidase inhibitor from a natural product to treat the hyperuricemia or the gout simultaneously.
Owner:山东新瑞生物科技有限公司
Tetrahydroindole derivatives as NADPH oxidase inhibitors
The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and / or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
Owner:GENKYOTEX SUISSE SA
Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
ActiveUS20130039854A1Easy to switchMinimize background noiseBiocidePowder deliveryEpitheliumCancer cell
A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
Owner:UNIV OF SOUTHERN CALIFORNIA
Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
ActiveUS20120329800A1Reduce and prevent productionImproving MDBiocideOrganic chemistryDuchenne muscular dystrophyMuscular dystrophy
Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.
Owner:UNIV DEGLI STUDI DI PADOVA
Use of beggarweed alkaloid monomer component
InactiveCN103816150AStrong inhibitory activityImproved stress behaviorOrganic active ingredientsNervous disorderAmine oxidase inhibitorsPharmaceutical drug
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Screening method for xanthine oxidase inhibitor and/or superoxide anion scavenging agent
InactiveCN103364519ARich varietyWider variety than UV spectrophotometryComponent separationFormazanScreening method
The invention discloses a method for fast screening a xanthine oxidase inhibitor or a superoxide anion scavenging agent by utilizing a coupling technique of thin-layer chromatography and bioautography. According to the method, the thin-layer chromatography is combined with biological activity assay, a superoxide anion free radical (O2<.->) generated by an enzymatic reaction reacts with nitroblue tetrazolium (NBT) to generate formazan which is a bluish violet insoluble substance, and substances capable of inhibiting xanthine oxidase or scavenging superoxide anion inhibit the reaction so yellow and / or white spots under a purple background show on a thin layer plate. The method is suitable for analyzing the in-vitro inhibition activity to the the xanthine oxidase or the scavenging activity to the superoxide anion of natural drugs and / or traditional Chinese medicine extracts or monomeric compounds.
Owner:SHANGHAI UNIV OF T C M
Medicinal compositions
ActiveUS20060241102A1Shorten the construction periodEffective treatmentBiocideNervous disorderTricyclic antidepressantAmine oxidase inhibitors
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Xanthine oxidase inhibitor
InactiveCN106146419AXanthine oxidase inhibitory effectOrganic active ingredientsOrganic chemistryDiseaseXanthine oxidase inhibitor
The invention belongs to the technical field of medicine and relates to 2-(3-cyano / nitro-4-substituted phenyl)-4-methyl-2(i)H( / i)-1,2,3-triazole-4-methane acid and formyl hydrazine compounds shown in the formula I, medicinal salt and medicinal solvate and a preparation method thereof. The substituent definition of the compounds is defined as claim books and manuals. The invention further relates to application of the compounds in preparation of medicine for treatment of hyperuricemia and gout diseases.
Owner:SHENYANG PHARMA UNIVERSITY
Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
Owner:VARINEL
Energy drinks and other nutritional aids derived from agave-based spirits
ActiveUS20160074343A1Destroy it activityNo lossOrganic active ingredientsBiocideAlcoholMonoamine oxidase inhibitor
Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.
Owner:ROAR HLDG
Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
Owner:VARINEL
Stilbene coumarin derivative as well as preparation method and application thereof
ActiveCN104892556ASimple processHigh reaction yieldOrganic active ingredientsOrganic chemistryMonoamine oxidase inhibitorType A Monoamine Oxidase
The invention discloses a stilbene coumarin derivative as well as a preparation method and an application thereof, and relates to the technical field of medicine synthesis. The structure general formula of the stilbene coumarin derivative is shown in formula (1) which is specified in the description. The synthesis process disclosed by the invention has the characteristics of being simple and practicable in reaction, and high in product yield; moreover, the synthesised stilbene coumarin derivative is good in inhibitory activity and selectivity on anthropogenic monoamine oxidases (hMAO-A and hMAO-B), and therefore can be used for preparing a monoamine oxidase inhibitor.
Owner:黄山市开发投资集团有限公司
Methods for preventing or treating bruxism using dopaminergic agents
InactiveUS20090247537A1Increasing dopaminergic activityAlleviates or eliminates one or more symptomsBiocideNervous disorderDiseaseMonoamine oxidase inhibitor
Methods for preventing or treating bruxism, including alleviating or eliminating one or more symptoms, diseases or conditions associated with or resulting from bruxism, using dopaminergic agents such as monoamine oxidase inhibitors that increase dopaminergic activity and dopamine agonists, are disclosed.
Owner:OVERFIELD WILLIAM DALE
Xanthine oxidase inhibitor and application thereof
The invention discloses a xanthine oxidase inhibitor and application thereof. The xanthine oxidase inhibitor is a compound shown as a general formula (I) and is a pharmaceutically acceptable salt. The xanthine oxidase inhibitor, which is the compound and the pharmaceutically acceptable salt, can be applied to preparation of the xanthine oxidase inhibitor and particularly applied to preparation of medicines for preventing or treating hypeluricemia diseases, gout or diabetic nephropathy.
Owner:JIANGSU ATOM BIOSCI & PHARMA CO LTD
Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
ActiveUS9771625B2Preferentially uptakenEasy to switchPowder deliveryOrganic active ingredientsAptamerEpithelium
Owner:UNIV OF SOUTHERN CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com